Lupus (SLE): vizsgálatok itt: Egyesült Királyság
16 of 18 trials · From ClinicalTrials.gov, checked 2026. november 19.. Ask the study team whether a trial fits you.
- 1/2. fázisVisszavonvaA Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
- Where
- Bristol
- Életkor
- 18 év to 70 év
- People
- 150 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06897930 - 2. fázisTaking peopleA Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- Where
- Basingstoke, Belfast, Cambridge, Doncaster
- Életkor
- 18 év to 74 év
- People
- 405 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07409181 · EU 2025-523488-39-00 - 3. fázisNot yet taking people in Egyesült KirályságRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Cambridge, Leeds, London, Newcastle upon Tyne, Sheffield
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- Where
- London, Newcastle upon Tyne
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07332481 · EU 2025-523871-44-00 - 3. fázisTaking peopleA Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- Where
- Doncaster, London, Walsall
- Életkor
- 18 év to 75 év
- People
- 202 worldwide
- Run by
- EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07355218 · EU 2025-524855-30-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Where
- Glasgow, Liverpool, London
- Életkor
- 5 év to 17 év
- People
- 40 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05039619 · EU 2023-505825-15-00 - 3. fázisTaking peopleA Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- Where
- Bath, Cambridge, Greater London, Newcastle upon Tyne, Peterborough, Reading, Southampton, Stoke-on-Trent, Swindon
- Életkor
- 18 év to 75 év
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07438496 · EU 2025-523552-31-00 - No phaseTaking peopleEffect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus Study
- Where
- Cambridge
- Életkor
- 18 év to 70 év
- People
- 15
- Run by
- University of Cambridge
See details and how to joinNCT07913919 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Where
- Bath, Belfast, Leeds, London, Newcastle upon Tyne, Sheffield, West Bromwich
- Életkor
- 16 év and over
- People
- 450 worldwide
- Run by
- UCB Biopharma SRL
See details and how to joinNCT06617325 · EU 2023-508191-11-00 - 2. fázisTaking peopleObe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
- Where
- Birmingham, Bristol, Cambridge, Edinburgh, Glasgow, London, Manchester
- Életkor
- 12 év to 65 év
- People
- 35 worldwide
- Run by
- Autolus Limited
See details and how to joinNCT07053800 · EU 2024-519941-32-00 - 1. fázisNot yet taking people in Egyesült KirályságStudy Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
- Where
- London
- Életkor
- 18 év to 65 év
- People
- 48 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07201558 · EU 2025-522273-10-00 - 1. fázisTaking peopleA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
- Where
- Glasgow, London, Southampton
- Életkor
- 18 év to 70 év
- People
- 72 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00 - 3. fázisCsak meghívásosA Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
- Where
- Cannock, Doncaster, London
- Életkor
- 18 év and over
- People
- 864 worldwide
- Run by
- Biogen
See details and how to joinNCT05352919 · EU 2023-505635-13-00 - 2. fázisTaking peopleA Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
- Where
- Cambridge, Edinburgh, Leicester, Newcastle upon Tyne
- Életkor
- 18 év to 75 év
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06570798 - 3. fázisTaking peopleAn Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
- Where
- Birmingham, Bristol, Liverpool, London, Manchester, Southampton
- Életkor
- 5 év to 17 év
- People
- 100 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05835310 · EU 2022-502289-25-00 - 1. fázisTaking peopleA Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Where
- Cambridge, London, Manchester
- Életkor
- 12 év to 70 év
- People
- 244 worldwide
- Run by
- Fate Therapeutics
See details and how to joinNCT06308978